Claims for Patent: 10,869,869

Summary for Patent: 10,869,869

Title:	Method of adjuvant cancer treatment
Abstract:	The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).
Inventor(s):	Laquerre; Sylvie (King of Prussia, PA), Lebowitz; Peter F. (Research Triangle Park, NC)
Assignee:	Novartis AG (Basel, CH)
Application Number:	16/664,978
Patent Claims:	1. A method for providing adjuvant treatment to a patient with a prior diagnosis of melanoma which has been resected, comprising the steps of: a) administering to said patient therapeutically effective doses of dabrafenib and trametinib, wherein said dabrafenib is administered at an amount of 150 mg twice a day and said trametinib is administered at an amount of 2 mg once daily; and b) increasing relapse-free (RFS) of said patient after resection of said melanoma. 2. The method of claim 1, wherein said patient has a prior diagnosis of stage III melanoma, which has been resected. 3. The method of claim 1, wherein said patient has a prior diagnosis of BRAF V600 mutation-positive melanoma, which has been resected.